Eli Lilly Is Dominating the GLP-1 Market: Here's What a $5,000 Investment Could Look Like in 5 Years

Eli Lilly Is Dominating the GLP-1 Market: Here's What a $5,000 Investment Could Look Like in 5 Years

Key PointsEli Lilly could capitalize on the growing GLP-1 market and deliver strong returns through 2031.However, investors need to keep several risks in mind. 10 stocks we like better than Eli Lilly › The first GLP-1 medicine was approved in the U.S. in 2005. It would take over a decade for drugs in this category to become household names. Brands such as Ozempic, Wegovy, and Zepbound are now well-known -- and the maker of the last of these, Eli…